Haemonetics names Frank Chan COO and promotes Roy Galvin to Chief Commercial Officer
Haemonetics appointed Frank W. Chan, Ph.D., former President of Medtronic's Acute Care & Monitoring business, as Executive Vice President and Chief Operating Officer, effective April 7, 2025, and promoted Roy Galvin to Executive Vice President and Chief Commercial Officer effective immediately. The filing describes these as leadership changes in the executive team; it reports no financial results or guidance, so it does not change reported figures.
Key points
- Frank W. Chan, Ph.D., 55, starts as COO on April 7, 2025, overseeing R&D, regulatory, global manufacturing and supply chain, and reporting to CEO Christopher A. Simon
- Chan's pay includes a $550,000 base salary, a target bonus of 80% of base salary, and a long-term equity award target value of $1,600,000, subject to Compensation Committee approval
- Chan receives a $350,000 sign-on bonus, with $300,000 repayable in the first 12 months and $150,000 repayable between months 12 and 24 if he leaves voluntarily or is terminated for cause
- Roy Galvin's expanded CCO role covers Global Hospital, Global Plasma and Blood Center; Stewart Strong, President, Global Hospital, stays in his role through April 1, 2025, then advises the CEO temporarily
The filing
Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 03, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.